Bio-Chemical Angioplasty also known, as Chelation Therapy is a treatment for coronary artery disease. After a long research and lots of experiments Saaol heart center started to treat patients with BCA and a lifestyle program in 50+ hospitals of Saaol all over India.
WHAT IS BCA/CHELATION THERAPY?
Chelation is a chemical process in which a substance is used to bind molecules, such as metals or minerals, and hold them tightly so that they can be removed from the body. In 1900 it was used to remove excess lead from the body for people who has lead poisoning. American organisations came forward to use EDTA CHELATION THERAPY as a treatment for Coronary artery Disease.
In 1988, a retrospective study of 2870 patients treated with EDTA chelation found that 77% of patients with ischemic heart disease showed “marked” improvement and 91% of patients with peripheral heart disease also showed “marked” improvement. A 1993 retrospective study of 470 patients who underwent EDTA chelation noted that 80% had objective evidence of improvements of their symptoms.
HOW DOES BCA WORK?
During a research by a medical organisation, they found a chemical factory shutting down their factory for 10 days every month. Later they found out due to lot of chemical passes thru their pipes, they react with the wall of the pipes and create plaque like obstructions.
Ultimately the pipe gets choked from inside. To clear pipes they were sending some opposite chemicals in the same tube and the plaques are removed. BCA works on same principals. Cleans arteries and thru urine bring everything out of body.
WHAT BCA CONTAINS?
A team of scientist took a sample of blockage that causes heart disease in human body to research what it is made of. Measure part of blockage made with cholesterol and triglyceride.
HOW SAAOL TREATS PATIENTS WITH BCA?
We use a mixture of biochemical with correct dosage according to body and injects in the patient through intravenous route.
It takes 2 and half hours of period to obtain softening of the blockage and a gradual reduction of blockage. In 6 to 10 infusions it shows significant result. It affects more with 20 infusions. There must be at least 1 days gap Between 2 infusions.
TACT STUDY BY NIH REPORTS
TACT study by NIH Reports to American Heart Association About Bio-Chemical Angioplasty TACT (Trial to Assess Chelation Therapy) Study by NIH of EDTA Chelation Therapy Proves Highly Significant Benefits in cardiovascular disease . “Up to 50% prevention of recurrent heart attacks and 43 percent reduction in death rate from all causes.” “The patients with diabetes, which made up approximately one third of 1,708 participants, demonstrated a 41 percent overall reduction in the risk of any cardiovascular event. This included a 40 percent reduction in the risk of death from heart disease, reduced risk of nonfatal stroke, or nonfatal heart attack; a 52 percent reduction in recurrent heart attacks; and a 43 percent reduction in death from any cause.”
Therapy (TACT). This randomized, placebo-controlled study of 1,708 patients showed that intravenous disodium EDTA chelation therapy decreased subsequent cardiac events with statistical significance, when compared to a control group of similar patients who received placebo. Cardiologists from prestigious medical schools joined a total of 134 medical centers across the U.S. and Canada who participated in this study, at a cost of $30 million. Statistical analysis showed benefits to be highly significant. Cardiac events that were reduced included fewer deaths, fewer heart attacks, and fewer strokes, less need for cardiovascular surgery, and fewer hospitalizations for heart problems. Chelation therapy shown to be safe, without any serious side effects. Patients experienced increasing benefits during the time that they were studied-up to five years thus far. Forty 3-hour intravenous infusions of disodium EDTA were administered during 30 weekly sessions, followed by 10 more treatments once per month. All patients in the study had previously suffered with a well documented heart attack. Results showed effectiveness at reducing their overall death rate, with fewer heart and vascular events. Diabetic patients appeared to do particularly well. The investigators concluded that intravenous EDTA chelation therapy can safely provides important benefits for heart disease patients, who were already on more traditional therapies before receiving chelation. These findings were unexpected by cardiologists, who have long disparaged EDTA chelation therapy. Additional research will be sought to confirmation these findings. Studies to explore the mechanism of action are also needed.